Pharmacologic considerations in determining efficacy of once-daily sotalol administration to hypertensive patients

Journal of Clinical Pharmacology
R Pasquel

Abstract

The beta-adrenergic blocker sotalol, administered only once a day, proved an extremely effective and safe agent for the 24-hour control of essential hypertension, even in patients with a severe form of the disease. Significant (P less than 0.01) decreases from the baseline levels were noted in both supine and standing blood pressures as early as the first week after sotalol administration in the 15 patients who participated in the open study. All patients were titrated and controlled by six to eight weeks or sooner. By the conclusion of the 12-week study, mean supine systolic blood pressure in the 15 patients fell 21 per cent (from 176 mm Hg to 139 mm Hg), and mean supine diastolic blood pressure was down 23 per cent (from 115 mm Hg to 89 mm Hg). Standing values were similarly decreased by sotalol administration at a mean daily dose of 341 mg. Two of the patients also received concomitant 25 mg hydrochlorothiazide per day, and four received 40 mg furosemide per day. A comparison with the pretherapy placebo values indicates that all the declines were highly significant (P less than 0.001). Sotalol was very well tolerated, an no adverse reactions were reported during the entire study. There were also no significant changes in lab...Continue Reading

References

May 1, 1977·Clinical Pharmacology and Therapeutics·D G McDevittR G Shanks
May 23, 1977·JAMA : the Journal of the American Medical Association
Jul 17, 1976·British Medical Journal·D B GallowayW T Simpson
Mar 11, 1977·European Journal of Clinical Pharmacology·A LehtonenT Kleimola
Apr 1, 1977·British Journal of Clinical Pharmacology·A J WOOD
Jul 3, 1976·British Medical Journal·H L Shaw
Jul 1, 1976·Clinical Science and Molecular Medicine·A VernioryM Telerman
Mar 22, 1976·European Journal of Clinical Pharmacology·H C BrownR G Shanks
Jul 19, 1975·British Medical Journal·H J Waal-Manning, F O Simpson
Nov 1, 1975·British Medical Journal·P BjerleG Agert
Apr 22, 1976·The New England Journal of Medicine·O B Holland, N M Kaplan
Apr 3, 1976·British Medical Journal·H Saarimaa
Sep 1, 1974·Clinical Pharmacology and Therapeutics·H SundquistM Arstila
Jan 1, 1974·European Journal of Clinical Pharmacology·R GuglerH J Dengler
Oct 1, 1969·European Journal of Pharmacology·N SvedmyrR Malmberg

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.